High LYVE-1–Positive Lymphatic Vessel Numbers Are Associated with Poor Outcome in Breast Cancer

• Petri Bono

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

• Veli-Matti Wasenius

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

• Päivi Heikkilä

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

• Johan Lundin

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

• David G. Jackson

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

• Heikki Joensuu

  Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; Medical Research Council Human Immunology Unit, Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

抄録

Purpose: The clinical significance of intratumoral or peritumoral lymph vessel density is not known. LYVE-1, a lymphatic endothelium-specific hyaluronan receptor, is a novel lymphatic vessel marker that is expressed on lymph vessel endothelial cells of both normal and neoplastic tissues. Experimental Design: We investigated expression of LYVE-1 by immunhistochemistry in 180 unilateral, invasive ductal breast carcinomas and assessed the presence and density of lymph vessels within the tumor and at the tumor periphery. Results: A minority (12%) of breast carcinomas had intratumoral lymph vessels, whereas peritumoral lymph vessels were identified in almost all cases (94%). No substantial association was found between the number of LYVE-1–positive vessels and the number of CD31 or vascular endothelial growth factor receptor-3–positive vessels, or vascular endothelial growth factor-C expression. The number of metastatic axillary lymph nodes increased in parallel with increasing lymph vessel counts (P = 0.033). A higher than the median lymph vessel count at the tumor periphery was significantly associated with unfavorable distant disease-free survival and overall survival. Women with high peritumoral lymph vessel density had only 58% (95% confidence interval, 46–70%) 5-year distant disease-free survival as compared with 74% (66–83%) among those with a low peritumoral lymph vessel density (P = 0.0088). In contrast, the presence of intratumoral lymph vessels was associated with neither axillary nodal status nor survival. Lymph vessel density was not an independent prognostic factor in a multivariate survival analysis. Conclusions: A high peritumoral lymph vessel density is associated with a poor outcome in ductal breast cancer.

収録刊行物

• Clinical Cancer Research

  Clinical Cancer Research 10 (21), 7144-7149, 2004-11-01

  American Association for Cancer Research (AACR)

キーワード

• Cancer Research
• Oncology

詳細情報

• CRID: 1360574095326093440
• NII論文ID: 30018692345
• DOI: 10.1158/1078-0432.ccr-03-0826
• ISSN: 15573265
• ISSN: 10780432
• ISSN: http://id.crossref.org/issn/10780432
• Web Site: https://aacrjournals.org/clincancerres/article-pdf/10/21/7144/1954331/zdf02104007144.pdf
• データソース種別:
  • Crossref
  • CiNii Articles